{
    "id": 24020,
    "cites": 40,
    "cited_by": 1,
    "reference": [
        "Trusheim, Mark R., Ernst R. Berndt and Frank L. Douglas, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Stratified Medicine: Strategic and Economic Implications of Combining Drugs and Clinical Biomarkers\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Nature Reviews: Drug Discovery, April 2007, 6(4):287-293.",
        "Hu, Sean X., Murray L. Aitken, Arnold M. Epstein, Mark R. Trusheim and Ernst R. Berndt, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Defining and Quantifying the Use of Personalized Medicines\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Nature Reviews: Drug Discovery, online version published 29 November 2013, http://www.nature.com/nrd/journal/v12/n12/full/nrd4177.html?WT.ec_id=NRD-201312. Hard copy version published December 2013.",
        "Novartis press release. Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL. July 13, 2017. https://www.novartis.com/news/media-releases/novartis-car-t-celltherapy -ctl019-unanimously-10-0-recommended-approval-fda , Accessed August 22, 2017.",
        "Press Release. Sanpower Group closes acquisition of Dendreon. June 29, 2017. Available at http://www.dendreon.com/Portals/188/DENDREON%20PRESS%20RELEASE.pdf . Accessed August 22, 2017. OR Reuters staff. BRIEF-Valeant pharmaceuticals completes sale of Dendreon to Sanpower Group. Reuters. June 29, 2017. http://www.reuters.com/article/brief-valeantpharmaceuticals -completes-idUSFWN1JQ07C Accessed August 22,2017.",
        "FDA. Cellular & Gene Therapy Products-Marketed Products. Food and Drug Administration. https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts /default.htm Page updated August 11, 2017. Accessed August 22, 2017.",
        "Trusheim, Mark R., Breon Burgess, Sean Xinghua Hu, Theresa Long, Steven D. Averbuch, Aiden A. Flynn, Alfons Lieftucht et al. Quantifying factors for the success of stratified medicine. Nature Reviews: Drug Discovery 10, no. 11 (2011): 817.",
        "US Food and Drug Administration. Remicade (infliximab) label, revised: January 2015. US Food and Drug Administration. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ (2015).",
        "Helwick, C. Pathologic complete response: Understanding the subtleties. The ASCO Post 5(16) October 15, 2014. accessed on 5/4/2015. Available at http://www.ascopost.com/issues/october-15,-2014/pathologic-complete-responseunderstanding -the-subtleties.aspx (2014).",
        "Ainsworth R., et al. IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest\u00c3\u00a2\u00e2\u0080\u009e\u00c2\u00a2 in breast carcinoma. J. Clin. Pathol. 58 1086-1090 (2005).",
        "Birner P., et al. Evaluation of the United States Food and Drug Administration-approved Scoring and Test System of HER-2 Protein Expression in Breast Cancer. Clin. Can. Res. 7 16691675 (2001).",
        "Hu, Sean X., Murray L. Aitken, Arnold M. Epstein, Mark R. Trusheim and Ernst R. Berndt, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Defining and Quantifying the Use of Personalized Medicines\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Nature Reviews: Drug Discovery, online version published 29 November 2013, http://www.nature.com/nrd/journal/v12/n12/full/nrd4177.html?WT.ec_id=NRD-201312. Hard copy version published December 2013.",
        "Trusheim, Mark R., and Ernst R. Berndt, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The clinical benefits, ethics, and economics of stratified medicine and companion diagnostics\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Drug Discovery Today 20(12): 14391450, December 2015.",
        "Robert S. Pindyck and Daniel L. Rubinfeld, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Game Theory and Competitive Strategy\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, ch. 13 in Pindyck and Rubinfeld, Microeconomics, Eighth Edition, New York: Pearson Education, Inc., publishing as Prentice Hall, 2013, 487-528.",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "Westwood M, van Asselt T, Ramaekers B, et al. Health Technology Assessment, No. 18.62. Chapter 3 Table 8 Accuracy of KRAS mutation testing for the prediction of response to treatment with cetuximab in addition to chemotherapy. Southampton (UK): NIHR Journals Library; 2014 Oct",
        "Bae Y.H. Mullins C. D. Do value thresholds for oncology drugs differ from nononcology drugs? J. Manag Care Pharm, 20(11):1086-92. (Nov 2014).",
        "FDA. Keytruda label. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "Staton, T. Bristol-Myers&apos; Opdivo far outpaced Merck&apos;s Keytruda again in Q2. What gives? FiercePharma August 1, 2016. http://www.fiercepharma.com/marketing/bristol-myers-opdivo-far-outpacedmerck -s-keytruda-again-q2-what-gives Accessed August 27, 207.",
        "Pollack, A. Immunotherapy drug Opdivo fails clinical trial to expand use. New York Times. August 5, 2016. https://www.nytimes.com/2016/08/06/business/lung-cancer-drug-opdivo-failsclinical -trial-to-expand-use.html?mcubz=1 Accessed August 27, 2017.",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "Carlson B. KRAS testing: Optimizing Cancer Therapy. Biotechnoloyg Healthcare. 6(5):7-9 Winter 2009-2010.",
        "FDA. Table of Pharmacogenomic Biomarkers in Drug Labelling. FDA. Available at https://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/uc m083378.htm. Accessed August 27, 2017.",
        "Gardiner, S.J. and Begg, E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacological reviews, 58(3):521-590 (2006).",
        "NICE. Bortezomib monotherapy for relapsed multiple myeloma. NICE technology appraisal guidance 129. Issue date October 2007. Review date October",
        "Press release. Adaptive Biotechnologies Announces a Collaboration with Janssen Biotech, Inc. to use the clonoSEQ Assay to Measure Minimal Residual Disease in Ongoing and Future DARZALEX Multiple Myeloma Trials. July 21, 2017. Available at http://www.adaptivebiotech.com/news/adaptive-biotechnologiesannounces -collaboration-janssen-biotech-inc-use-clonoseq%C2%AE-assay Accessed August 27, 2017.",
        "Pindyck, RS, Rubinfeld DL. Microeconomics Eighth Edition. pp:499-500, Pearson Education, 2013.",
        "Berndt ER, MCGuire TG, Newhouse JP. A primer on the economics of prescription pharmaceutical pricing in health insurance markets. Forum for Health Economics & Policy 14(2) article 10, November 2011.",
        "Danzon, Patricia M., Nuno Sousa Pereira, and Sapna S. Tejwani. Vaccine supply: a cross-national perspective. Health Affairs 24, no. 3 (2005): 706-717.",
        "Berndt, E.R., Denoncourt, R.N. and Warner, A.C. US markets for vaccines: characteristics, case studies, and controversies. AEI Press. (2009).",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "CDC. Hepatitis C Information on Testing and Diagnosis. Centers for Disease Control. Available at https://www.cdc.gov/hepatitis/hcv/pdfs/hepctestingdiagnosis. pdf , Accessed August 31, 2017.",
        "Pollack, A. FDA approves pill to treat Hepatitis C. New York Times, Page B1, New York Edition, December 7, 2013. Available at http://www.nytimes.com/2013/12/07/business/fda-approves-pill-to-treathepatitis -c.html?mcubz=1 . Accessed August 31, 2017.",
        "FDA. FDA Online Label Repository, available at http://labels.fda.gov/ (2017).",
        "Humer C. Express Scripts to cover AbbVie hepatitis C drug, drops Gilead treatment. Reuters. December 22, 2014. Available at http://www.reuters.com/article/express-scripts-abbvie-hepatitiscidUSL1N0U50M120141222 Accessed August 31, 2017.",
        "National Acquisition Center (CCST) Pharmaceutical Catalogue Search. US Department of Veterans Affairs. Available at https://www.va.gov/nac/Pharma/List, Accessed August 31, 2017.",
        "Berndt, E.R. and Trusheim, M.R. Biosimilar and Biobetter Scenarios for the US and Europe: What Should We Expect?. In Biobetters (pp. 315-360). Springer New York. (2015).",
        "Fudenberg, D. and Tirole, J., 1991. Game theory, chapter four. Cambridge, Massachusetts: MIT Press."
    ]
}